The third quarter was one of transition for both Orexigen and the Contrave franchise as Takeda stopped detailing the obesity drug in the United States and Orexigen took up the mantle. Contrave market share fell from 7% to 6% in wake of the announcement, but prescription data indicate it is stabilizing. Outside of the US, progress continues as the product has launched in South Korea and five countries in Central and Eastern Europe (CEE) with launches in another six CEE countries expected in Q4
18 Nov 2016
Contrave market share stabilizing
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Contrave market share stabilizing
- Published:
18 Nov 2016 -
Author:
Maxim Jacobs -
Pages:
5
The third quarter was one of transition for both Orexigen and the Contrave franchise as Takeda stopped detailing the obesity drug in the United States and Orexigen took up the mantle. Contrave market share fell from 7% to 6% in wake of the announcement, but prescription data indicate it is stabilizing. Outside of the US, progress continues as the product has launched in South Korea and five countries in Central and Eastern Europe (CEE) with launches in another six CEE countries expected in Q4